Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyTue, 23 Jul 2024 06:10:46 +0200Fri, 14 Jun 2024 11:11:11 +0200Lytenava : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5723-en.pdfLytenava : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5723-en.pdfFri, 14 Jun 2024 11:11:11 +0200Human medicineHuman medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/lytenavaHuman medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/lytenavaFri, 31 May 2024 17:30:00 +0200Human medicine